Insider Selling: Biopharmx Corp (BPMX) Major Shareholder Sells $59,278.80 in Stock

Biopharmx Corp (NYSEAMERICAN:BPMX) major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Biopharmx Corp (NYSEAMERICAN BPMX) remained flat at $$0.19 during trading on Thursday. The stock had a trading volume of 679,100 shares, compared to its average volume of 1,349,153. Biopharmx Corp has a 52-week low of $0.16 and a 52-week high of $0.90.

Biopharmx Corp (NYSEAMERICAN:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at

A number of research analysts recently issued reports on BPMX shares. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research report on Tuesday, September 19th. Maxim Group decreased their target price on shares of Biopharmx Corp from $3.00 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, September 13th.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply